OBJECTIVES: To evaluate the efficacy of low and medium dose aspirin therapy after coronary surgery by using an indirect comparison meta-analysis. DATA SOURCES: Systematic literature search of Medline, Embase, Cochrane controlled trials register, and trial register sites on the internet. STUDY SELECTION: Outcome was evaluated by angiography and reported as graft occlusion and rate of events in patients. Trials that did not include aspirin as the sole therapy or did not have a placebo control arm were excluded. Articles were assessed for eligibility and quality and grouped according to dosage. The estimated difference in effect of low and medium dose aspirin on graft occlusion was obtained by combining the estimated log relative risks of low dose with placebo and medium dose with placebo. RESULTS: For graft occlusion, the medium dose trials yielded a relative risk reduction of 45% compared with 26% for the low dose trials. The greater effect in the medium dose trials is summarised by a relative risk ratio of 0.74 (95% confidence interval 0.52 to 1.06; P = 0.10) for graft occlusion and 0.81 (0.57 to 1.16; P = 0.25) for events in patients. CONCLUSIONS: Medium dose aspirin may more successfully reduce graft occlusion than low dose regimens within the first year after coronary surgery.
OBJECTIVES: To evaluate the efficacy of low and medium dose aspirin therapy after coronary surgery by using an indirect comparison meta-analysis. DATA SOURCES: Systematic literature search of Medline, Embase, Cochrane controlled trials register, and trial register sites on the internet. STUDY SELECTION: Outcome was evaluated by angiography and reported as graft occlusion and rate of events in patients. Trials that did not include aspirin as the sole therapy or did not have a placebo control arm were excluded. Articles were assessed for eligibility and quality and grouped according to dosage. The estimated difference in effect of low and medium dose aspirin on graft occlusion was obtained by combining the estimated log relative risks of low dose with placebo and medium dose with placebo. RESULTS: For graft occlusion, the medium dose trials yielded a relative risk reduction of 45% compared with 26% for the low dose trials. The greater effect in the medium dose trials is summarised by a relative risk ratio of 0.74 (95% confidence interval 0.52 to 1.06; P = 0.10) for graft occlusion and 0.81 (0.57 to 1.16; P = 0.25) for events in patients. CONCLUSIONS: Medium dose aspirin may more successfully reduce graft occlusion than low dose regimens within the first year after coronary surgery.
Authors: G A Pantely; S H Goodnight; S H Rahimtoola; B J Harlan; H DeMots; L Calvin; J Rösch Journal: N Engl J Med Date: 1979-11-01 Impact factor: 91.245
Authors: J H Chesebro; V Fuster; L R Elveback; I P Clements; H C Smith; D R Holmes; W T Bardsley; J R Pluth; R B Wallace; F J Puga Journal: N Engl J Med Date: 1984-01-26 Impact factor: 91.245
Authors: J H Chesebro; I P Clements; V Fuster; L R Elveback; H C Smith; W T Bardsley; R L Frye; D R Holmes; R E Vlietstra; J R Pluth; R B Wallace; F J Puga; T A Orszulak; J M Piehler; H V Schaff; G K Danielson Journal: N Engl J Med Date: 1982-07-08 Impact factor: 91.245
Authors: B B Weksler; S B Pett; D Alonso; R C Richter; P Stelzer; V Subramanian; K Tack-Goldman; W A Gay Journal: N Engl J Med Date: 1983-04-07 Impact factor: 91.245
Authors: M T McEnany; E W Salzman; E D Mundth; R W DeSanctis; J W Harthorne; R M Weintraub; S Gates; W G Austen Journal: J Thorac Cardiovasc Surg Date: 1982-01 Impact factor: 5.209
Authors: Margreet R de Vries; Karin H Simons; J Wouter Jukema; Jerry Braun; Paul H A Quax Journal: Nat Rev Cardiol Date: 2016-05-19 Impact factor: 32.419
Authors: Eric Lim; Jacqueline Cornelissen; Tom Routledge; Ayyaz Ali; Stephen Kirtland; Linda Sharples; Kate Sheridan; Sarah Bellm; Helen Munday; Stephen Large Journal: BMC Med Date: 2006-05-22 Impact factor: 8.775